Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alector, Inc. - Common Stock
(NQ:
ALEC
)
1.870
-0.210 (-10.10%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alector, Inc. - Common Stock
< Previous
1
2
3
Next >
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
October 07, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
October 05, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
September 03, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
August 06, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 07, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Alector, Inc.
Via
GlobeNewswire
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
December 12, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Bank of America CNS Therapeutics Conference
December 01, 2025
From
Alector, Inc.
Via
GlobeNewswire
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
November 26, 2025
From
Schall Law
Via
GlobeNewswire
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
November 19, 2025
From
Schall Law
Via
GlobeNewswire
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
November 11, 2025
From
The Schall Law Firm
Via
Business Wire
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
October 21, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
September 16, 2025
--Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates--
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
August 28, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
July 31, 2025
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Provides Executive Leadership Update
June 13, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
May 06, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
April 17, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Provides Executive Leadership Update
March 28, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
February 25, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
February 19, 2025
Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
January 13, 2025
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
November 25, 2024
From
Alector, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
